JP2012515801A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515801A5
JP2012515801A5 JP2011548230A JP2011548230A JP2012515801A5 JP 2012515801 A5 JP2012515801 A5 JP 2012515801A5 JP 2011548230 A JP2011548230 A JP 2011548230A JP 2011548230 A JP2011548230 A JP 2011548230A JP 2012515801 A5 JP2012515801 A5 JP 2012515801A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
composition according
pterocin
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011548230A
Other languages
English (en)
Japanese (ja)
Other versions
JP5640019B2 (ja
JP2012515801A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/022129 external-priority patent/WO2010085811A2/en
Publication of JP2012515801A publication Critical patent/JP2012515801A/ja
Publication of JP2012515801A5 publication Critical patent/JP2012515801A5/ja
Application granted granted Critical
Publication of JP5640019B2 publication Critical patent/JP5640019B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011548230A 2009-01-26 2010-01-26 糖尿病及び肥満症を治療するためのプテロシン化合物の使用 Expired - Fee Related JP5640019B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14738209P 2009-01-26 2009-01-26
US61/147,382 2009-01-26
PCT/US2010/022129 WO2010085811A2 (en) 2009-01-26 2010-01-26 Use of pterosin compounds for treating diabetes and obesity

Publications (3)

Publication Number Publication Date
JP2012515801A JP2012515801A (ja) 2012-07-12
JP2012515801A5 true JP2012515801A5 (https=) 2013-03-14
JP5640019B2 JP5640019B2 (ja) 2014-12-10

Family

ID=42354647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548230A Expired - Fee Related JP5640019B2 (ja) 2009-01-26 2010-01-26 糖尿病及び肥満症を治療するためのプテロシン化合物の使用

Country Status (10)

Country Link
US (1) US8633252B2 (https=)
EP (1) EP2389171B1 (https=)
JP (1) JP5640019B2 (https=)
KR (1) KR101746867B1 (https=)
CN (1) CN102333528B (https=)
AU (1) AU2010206549B2 (https=)
CA (1) CA2749931C (https=)
NZ (1) NZ594236A (https=)
TW (1) TWI522109B (https=)
WO (1) WO2010085811A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160020472A (ko) * 2013-06-19 2016-02-23 액세스 비지니스 그룹 인터내셔날 엘엘씨 체중 관리의 지원을 위한 케토헥소키나제의 식물 기반 저해제
CN106831386A (zh) * 2015-12-04 2017-06-13 江西中医药大学 新型蕨素类化合物在治疗糖尿病的应用
CN105878220B (zh) * 2016-04-21 2019-02-05 广州市爱菩新医药科技有限公司 倍半萜类化合物在制备防治高血脂药物中的应用
CN107232497A (zh) * 2017-06-01 2017-10-10 河北农业大学 一种具有降血脂功能的膨化食品及其制备方法
US20220257532A1 (en) * 2017-06-16 2022-08-18 Korpharm Co., Ltd. Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
CN108576355B (zh) * 2018-03-27 2021-11-09 百色学院 一种蕨菜多糖含片及其制备方法
CN110156738B (zh) * 2019-06-26 2023-01-03 中北大学 一种伊鲁烷型倍半萜反应中间体及天然产物的全合成方法
EP4260850A4 (en) * 2020-12-14 2024-10-16 GHPharm Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING A PTEROSIN COMPOUND AND A DERIVATIVE THEREOF AS AN ACTIVE INGREDIENT, FOR THE PREVENTION OR TREATMENT OF A PKA-ASSOCIATED DISEASE
KR20260019211A (ko) 2024-08-01 2026-02-10 주식회사 지에이치팜 프테로신 d의 신규한 합성 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745104A (en) * 1985-04-15 1988-05-17 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
US4849410A (en) * 1985-04-15 1989-07-18 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
JPS63146839A (ja) 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk プテロシン系化合物を含んで成る制癌剤
JPH02237932A (ja) * 1989-03-10 1990-09-20 Yokichi Mochizuki 結石等の治療剤
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
AU668818B2 (en) * 1993-04-07 1996-05-16 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
FR2777566B1 (fr) * 1998-04-15 2003-02-21 Synthelabo Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142668A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
BRPI0309689B1 (pt) * 2002-04-30 2021-06-29 Unigen, Inc Composições compreendendo uma mistura de flavonóides de anel-b-livre e flavanos e usos das mesmas
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
CA2505322A1 (en) * 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
BRPI0407893A (pt) * 2003-02-26 2006-03-01 Unigen Pharmaceuticals Inc formulação para uso na prevenção e tratamento de doenças e condições induzidas por carboidrato
AU2004286857A1 (en) * 2003-11-04 2005-05-19 Merck & Co., Inc. Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
PL1756084T3 (pl) * 2004-06-04 2009-06-30 Arena Pharm Inc Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
EP1830804A2 (en) * 2004-12-06 2007-09-12 Reliant Pharmaceuticals, Inc. Stable compositions of fenofibrate with fatty acid esters
FR2880885B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'acide phenylbenzoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
KR20070107108A (ko) * 2005-02-05 2007-11-06 아스트라제네카 아베 화학적 화합물
EP1924546A1 (en) * 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity

Similar Documents

Publication Publication Date Title
JP2012515801A5 (https=)
RU2490250C2 (ru) Спиросоединения и их фармацевтическое применение
JP2012505836A5 (https=)
JP2013508279A5 (https=)
RU2664534C9 (ru) Пролекарственная форма тенофовира и ее фармацевтические применения
RU2015100901A (ru) Производные эфира гетероарилкарбоновой кислоты
JP2010523522A5 (https=)
JP2010514832A5 (https=)
JP2013534248A5 (https=)
JP2013519632A5 (https=)
JP2011528350A5 (https=)
JP2009530398A5 (https=)
JP2013545785A5 (https=)
IL314360A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
JP2016503052A5 (https=)
RU2009120534A (ru) Новые липидные соединения
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
RU2013147629A (ru) Соединения для лечения метаболического синдрома
JP2011516511A5 (https=)
JP2010090149A5 (https=)
JP2011519360A5 (https=)
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
JP2012523395A5 (https=)
RU2011145054A (ru) Кристаллические формы саксаглиптина
US20200093841A1 (en) Broad Spectrum Antiviral and Methods of Use